Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Syed Sameer Nasir (NPI 1801103643)

Field	Value
Entity Type	Individual
Organization	Syed Sameer Nasir
Address	7945 Wolf River Blvd
City	Germantown
State	TN
ZIP	38138
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 31, 2010

Payer Source	Total Paid
Medicare	$3.5M
Medicaid	$0

Key Findings

This provider’s billed Medicare volume dominates its public-payer footprint: total Medicare revenue is $3.5M while there is no Medicaid billing on file, making the practice effectively single-payer (Medicare) in publicly reported claims and revenue. The absence of Medicaid activity suggests limited state-plan exposure and that Medicare reimbursement trends will disproportionately affect the practice’s public revenue stream.

Revenue is highly concentrated in a small number of high-cost oncology drugs: the precomputed top 3 Medicare codes account for 70.5% of total Medicare revenue, led by J9271 at $1.4M (43.2%), followed by J9299 at $590.9K (17.7%) and J0897 at $325.1K (9.7%). This concentration indicates that a majority of Medicare dollars for this provider are driven by specific injectable cancer therapies rather than general office visits or diagnostic testing.

The CPT/HCPCS mix indicates an oncology infusion and supportive-care practice model: top codes include immunotherapies J9271 (pembrolizumab) and J9299 (nivolumab), chemotherapy administration codes such as 96413 and infusion management codes 96365/96367, and supportive agents like J2506 (pegfilgrastim) and J1437/J1439 (iron formulations). Together these codes point to on-site intravenous/infusional cancer treatment with associated supportive services (growth factors, iron, and transfusion/monitoring labs).

Competitive standing on key drugs is strong nationally for certain therapies: J9271 ranks #78 of 1841 providers nationally (96th percentile; notably above typical national volume), signaling unusually high pembrolizumab activity relative to peers. J9299 ranks #107 of 505 (79th percentile; typical, unremarkable volume) and J0897 ranks #356 of 10057 (96th percentile; notably above typical national volume), indicating leadership in some high-revenue biologics but more typical positioning on others.

Several codes show extreme/high outlier operational activity beyond drug administration alone: 99214 is an extreme outlier at the 99th percentile (#2953 of 479517 providers), while infusion-related and lab codes such as 96413 (98th percentile), 96367 (99th percentile), 36415 (99th percentile), and 80048/80076 (98–99th percentiles) are also well above typical national volumes. These patterns suggest both high clinical visit intensity and significant in-house procedural and laboratory throughput to support oncology care.

The provider demonstrates local leadership in biosimilar use and enrollment in enhanced oncology services: Q5107 (bevacizumab-awwb, mvasi) produced $181.5K (5.4% of Medicare revenue) and ranks #6 of 78 providers nationally (94th percentile), and M0010 (EOM monthly enhanced oncology services) ranks #9 of 544 (99th percentile) with $30.9K in revenue. High ranks on Q5107 and M0010 imply active adoption of biosimilars and participation in oncology-specific payment models or enhanced service billing.

Tenure on file is substantial and likely supports established referral patterns: NPI enumerated 2010-08-31 (~16 years ago), indicating the provider has been active for roughly a decade and a half. This longevity, combined with concentrated high-volume drug billing, is consistent with an established oncology practice rather than a recent entrant.

From a payer risk and contracting perspective, the combination of single-payer Medicare exposure and concentration in a few high-revenue oncology drugs (70.5% from the top three codes) creates revenue sensitivity to changes in Medicare drug pricing or utilization policy. The practice’s strong national ranks on specific biologics (notably J9271 and J0897) and high E/M volumes could make the provider an important target for network negotiations focused on oncology infusion services and high-cost drug utilization management.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

87 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	33,600	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	24,620	$20	$590.9K
J0897	Injection, denosumab, 1 mg	18,060	$20	$325.1K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	7,890	$20	$181.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,610	$90	$141.3K
J1437	Injection, ferric derisomaltose, 10 mg	4,600	$20	$73.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	820	$90	$72K
J1439	Injection, ferric carboxymaltose, 1 mg	63,750	$1	$63.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	710	$80	$58.8K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	120	$350	$41.9K

Showing 1–10 of 87

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 87 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Syed Sameer Nasir — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

87 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	50	17,400	$40	$776.1K
J9299	5	20	21,010	$20	$487.5K
J1437	9	20	3,700	$20	$86.3K
J0897	6	240	2,940	$20	$85K
Q5107	1	20	2,990	$20	$77.6K
J0881	36	70	19,050	$1	$54.4K
88185	8	30	690	$20	$51.2K
J2506	11	40	430	$80	$46.7K
J3490	2	60	70	$400	$41.9K
J1439	22	90	34,130	$1	$38.6K

Showing 1–10 of 87

Related Providers

Other providers that share a Tax Identification Number (TIN) with Syed Sameer Nasir, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The West Clinic P.C.	TN	Specialist	$0	$16M
David Portnoy	TN	Hematology & Oncology Physician	$6.5M	$0
University Of Maryland St. Joseph Medical Group, LLC	MD	General Practice Physician	$0	$6.2M
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Gang Tian	TN	Hematology & Oncology Physician	$3.8M	$0
Jason Chandler	TN	Medical Oncology Physician	$3.8M	$0
Ramakrishna Battini	TN	Hematology & Oncology Physician	$3.3M	$0
Eric Wiedower	TN	Hematology & Oncology Physician	$2.9M	$0
Bradley Somer	TN	Hematology & Oncology Physician	$2.8M	$0
Robert Johnson	TN	Hematology & Oncology Physician	$2.8M	$0

Nearby Providers

Other providers in the same ZIP code as Syed Sameer Nasir, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Byram Healthcare Centers, Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$44.3M
Campbell Clinic, PC	TN	Orthopaedic Surgery Physician	$0	$28M
Poplar Avenue Clinic PLLC	TN	Gynecologic Oncology Physician	$0	$9.7M
Diagnostic Ultrasound Consultants	TN	Diagnostic Radiology Physician	$0	$8.5M
Mid-south Imaging & Therapeutics, P.A.	TN	Diagnostic Radiology Physician	$0	$8.2M
Stephen Huddleston	TN	Retina Specialist (Ophthalmology) Physician	$5.7M	$0
Stern Cardiovascular Foundation, Inc	TN	Cardiovascular Disease Physician	$0	$4.7M
G I Diagnostic And Therapeutic Center LLC	TN	Endoscopy Clinic/Center	$4.2M	$8.6K
Memphis Neurology PLLC	TN	Neurology Physician	$0	$3.9M
Raza Hashmi	TN	Rheumatology Physician	$3.9M	$0

Syed Sameer Nasir — Billing Profile & Reimbursement Data

Sign up for Syed Sameer Nasir — Billing Profile & Reimbursement Data policy alerts

Syed Sameer Nasir — Billing Profile & Reimbursement Data

Sign up for Syed Sameer Nasir — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References